Lymphoma treatment programme

Publications from Lymphoma treatment programme

200 publications found

Publications in press

1. Eide MB, Liestol K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J
   Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
   Blood (in press)
   PubMed 20505157
2. Johnsen HE, Geisler C, Juvonen E, Remes K, Juliusson G, Hörnsten P, Kvaloy S, Kvalheim G, Jürgensen GW, Pedersen LM, Bergmann OJ, Schmitz A, Boegsted M
   Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment
   Bone Marrow Transplant (in press)
   PubMed 20436517
3. Tierens AM, Holte H, Warsame A, Ikonomou IM, Wang J, Chan WC, Delabie J
   Low levels of monoclonal small B-cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type
   Haematologica (in press)
   PubMed 20145271
4. Zaikova O, Fosså SD, Kongsgaard U, Kvaløy S, Giercksky KE, Skjeldal S
   Pain after Palliative Radiotherapy for Spine Metastases
   Clin Oncol (R Coll Radiol) (in press)
   PubMed 20363110

Publications 2010

1. Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2010)
   The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
   Blood, 115 (8), 1530-3
   PubMed 20032504
2. Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2010)
   Enhancement characteristics of lymphomatous lymph nodes of the neck
   Acta Radiol, 51 (5), 555-62
   PubMed 20429760
3. Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M (2010)
   Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
   Br J Haematol, 149 (2), 237-43
   PubMed 20201949
4. van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA (2010)
   BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study
   J Clin Oncol, 28 (13), 2246-52
   PubMed 20368567
5. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2010)
   Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
   J Clin Oncol, 28 (17), 2853-8
   PubMed 20439641

Publications 2009

1. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H, Nordström M, Fredén S, Jerkeman M, Eriksson M, Väärt J, Malmer B, Geisler CH (2009)
   Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma
   J Clin Oncol, 27 (26), 4365-70
   PubMed 19652064
2. Geisler C, Kolstad A, Laurell A, Räty R, Nordic Lymphoma Group, Mantle Cell Lymphoma Subcommittee (2009)
   Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?
   Leuk Lymphoma, 50 (8), 1249-56
   PubMed 19562619
3. Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB (2009)
   [Molecular diagnosis of malignant lymphomas]
   Tidsskr Nor Laegeforen, 129 (22), 2352-6
   PubMed 19935935
4. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R (2009)
   Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
   Blood, 114 (16), 3431-8
   PubMed 19641184
5. Jetne V, Kvaløy S, Smeland S, Johannesen TB, Tveit KM (2009)
   [Use of radiotherapy in South-Eastern Norway Regional Health Authority]
   Tidsskr Nor Laegeforen, 129 (24), 2602-5
   PubMed 20029555
6. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW (2009)
   Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens
   Clin Lymphoma Myeloma, 9 (4), 307-10
   PubMed 19717381
7. Kiserud CE, Fosså A, Bjøro T, Holte H, Cvancarova M, Fosså SD (2009)
   Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy
   Br J Cancer, 100 (3), 455-63
   PubMed 19156143
8. Kiserud CE, Schover LR, Dahl AA, Fosså A, Bjøro T, Loge JH, Holte H, Yuan Y, Fosså SD (2009)
   Do male lymphoma survivors have impaired sexual function?
   J Clin Oncol, 27 (35), 6019-26
   PubMed 19858388
9. O'Shea D, O'Riain C, Gupta M, Waters R, Yang Y, Wrench D, Gribben J, Rosenwald A, Ott G, Rimsza LM, Holte H, Cazier JB, Johnson NA, Campo E, Chan WC, Gascoyne RD, Young BD, Staudt LM, Lister TA, Fitzgibbon J (2009)
   Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation
   Blood, 113 (10), 2298-301
   PubMed 19141865
10. Wethal T, Lund MB, Edvardsen T, Fosså SD, Pripp AH, Holte H, Kjekshus J, Fosså A (2009)
    Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study
    Br J Cancer, 101 (4), 575-81
    PubMed 19623176
11. Zaikova O, Giercksky KE, Fosså SD, Kvaløy S, Johannesen TB, Skjeldal S (2009)
    A population-based study of spinal metastatic disease in South-East Norway
    Clin Oncol (R Coll Radiol), 21 (10), 753-9
    PubMed 19850454

Publications 2008

1. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH (2008)
   Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation
   Ann Oncol, 19 (11), 1935-40
   PubMed 18684698
2. Fosså SD, Kvaløy J, Kvaløy S, Loge JH, Dahl AA (2008)
   [Courses for cancer patients--15 years' experience at The Montebello Centre in Norway]
   Tidsskr Nor Laegeforen, 128 (22), 2554-7
   PubMed 19023349
3. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2008)
   Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
   Blood, 112 (7), 2687-93
   PubMed 18625886
4. Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C, Nordic Lymphoma Group (2008)
   Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group
   Leuk Lymphoma, 49 (1), 102-12
   PubMed 18203019
5. Kolstad A (2008)
   [Heart complications following cancer treatment]
   Tidsskr Nor Laegeforen, 128 (2), 187-8
   PubMed 18240394
6. Kolstad A, Tjønnfjord G, Jønsson V (2008)
   High frequency of unrecognized indolent hematological disorders among HLA-matched siblings of patients with lymphoproliferative malignancies eligible for allo-SCT
   Bone Marrow Transplant, 42 (6), 427-8
   PubMed 18587433
7. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2008)
   Stromal gene signatures in large-B-cell lymphomas
   N Engl J Med, 359 (22), 2313-23
   PubMed 19038878
8. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A (2008)
   Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
   J Clin Oncol, 26 (32), 5156-64
   PubMed 18854568
9. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International Trial (MInT) Group (2008)
   Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
   Lancet Oncol, 9 (5), 435-44
   PubMed 18400558
10. Torfoss D, Høiby EA, Holte H, Kvaløy S (2008)
    [Penicillin and aminoglycoside in febrile neutropenia]
    Tidsskr Nor Laegeforen, 128 (23), 2738-40
    PubMed 19079423

Publications 2007

1. Björkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Ståhl E, Myhre J, Pertovaara H, Ost A, Nilsson B, Osby E (2007)
   Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
   Ann Oncol, 18 (6), 1085-9
   PubMed 17363838
2. Kiserud CE, Fosså A, Holte H, Fosså SD (2007)
   Post-treatment parenthood in Hodgkin's lymphoma survivors
   Br J Cancer, 96 (9), 1442-9
   PubMed 17406362
3. Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D (2007)
   Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
   Haematologica, 92 (1), 139-40
   PubMed 17229653
4. Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H (2007)
   Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma
   Leuk Lymphoma, 48 (3), 570-6
   PubMed 17454601
5. Micci F, Panagopoulos I, Tjønnfjord GE, Kolstad A, Delabie J, Beiske K, Heim S (2007)
   Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies
   Virchows Arch, 450 (5), 559-65
   PubMed 17406891
6. Oldervoll LM, Loge JH, Kaasa S, Lydersen S, Hjermstad MJ, Thorsen L, Holte H, Jacobsen AB, Fosså SD (2007)
   Physical activity in Hodgkin's lymphoma survivors with and without chronic fatigue compared with the general population - a cross-sectional study
   BMC Cancer, 7, 210
   PubMed 17997822
7. Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S (2007)
   Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial
   J Antimicrob Chemother, 59 (4), 711-7
   PubMed 17327294
8. Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM (2007)
   Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
   Blood, 109 (11), 4599-606
   PubMed 17299095
9. Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J (2007)
   Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
   Ann Oncol, 18 (4), 694-700
   PubMed 17301072
10. Aamot HV, Torlakovic EE, Eide MB, Holte H, Heim S (2007)
    Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations
    J Cancer Res Clin Oncol, 133 (7), 455-70
    PubMed 17235551

Publications 2006

1. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2006)
   Molecular diagnosis of Burkitt's lymphoma
   N Engl J Med, 354 (23), 2431-42
   PubMed 16760443
2. Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR (2006)
   Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation
   Biol Blood Marrow Transplant, 12 (11), 1150-60
   PubMed 17085308
3. Haukvik UK, Dieset I, Bjøro T, Holte H, Fosså SD (2006)
   Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma
   Ann Oncol, 17 (9), 1428-33
   PubMed 16831852
4. Hjermstad MJ, Hollender A, Warloe T, Karlsen KO, Ikonomo I, Kvaloy S, Nome O, Holte H (2006)
   Quality of life after total or partial gastrectomy for primary gastric lymphoma
   Acta Oncol, 45 (2), 202-9
   PubMed 16546867
5. Hjermstad MJ, Oldervoll L, Fosså SD, Holte H, Jacobsen AB, Loge JH (2006)
   Quality of life in long-term Hodgkin's disease survivors with chronic fatigue
   Eur J Cancer, 42 (3), 327-33
   PubMed 16377179
6. Hollender A, Bjøro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H (2006)
   Vitamin D deficiency in patients operated on for gastric lymphoma
   Scand J Gastroenterol, 41 (6), 673-81
   PubMed 16716965
7. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006)
   CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
   Lancet Oncol, 7 (5), 379-91
   PubMed 16648042
8. Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
   Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
   Leukemia, 20 (3), 539-42
   PubMed 16437153
9. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A (2006)
   Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
   Blood, 108 (10), 3295-301
   PubMed 16873669

Publications 2005

1. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A, Lymphoma/Leukemia Molecular Profiling Project (2005)
   Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
   Blood, 106 (9), 3183-90
   PubMed 16046532
2. Fosså SD, Holte H, Holmen MM, Bjøro T, Langmark F, Hess SL, Kvaløy S (2005)
   [Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma]
   Tidsskr Nor Laegeforen, 125 (1), 41-4
   PubMed 15643464
3. Hjermstad MJ, Fosså SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH (2005)
   Fatigue in long-term Hodgkin's Disease survivors: a follow-up study
   J Clin Oncol, 23 (27), 6587-95
   PubMed 16170166
4. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL (2005)
   I-131-tositumomab therapy as initial treatment for follicular lymphoma
   N. Engl. J. Med., 352 (5), 441-449
5. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL (2005)
   131I-tositumomab therapy as initial treatment for follicular lymphoma
   N Engl J Med, 352 (5), 441-9
   PubMed 15689582
6. Kolstad A (2005)
   Letters to the editor on Norwegian psychiatry
   Hist. Psychiatr., 16 (2), 247-252
7. Mishra V, Andresen S, Brinch L, Kvaløy S, Ernst P, Lønset MK, Tangen JM, Wikelund J, Flatum C, Baggerød E, Helle B, Vaaler S, Hagen TP (2005)
   Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study
   Bone Marrow Transplant, 35 (12), 1149-53
   PubMed 15880133
8. Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J (2005)
   PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor
   J Pathol, 206 (3), 312-9
   PubMed 15892171
9. Aamot HV, Micci F, Holte H, Delabie J, Heim S (2005)
   G-banding and molecular cytogenetic analyses of marginal zone lymphoma
   Br J Haematol, 130 (6), 890-901
   PubMed 16156859

Publications 2004

1. Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G (2004)
   Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy
   Br J Haematol, 125 (5), 605-12
   PubMed 15147376
2. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004)
   Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
   N Engl J Med, 351 (21), 2159-69
   PubMed 15548776
3. Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH, Holte H, Kaasa S (2004)
   A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation
   Bone Marrow Transplant, 34 (3), 257-66
   PubMed 15170167
4. Husebekk A, Skaug K, Kolstad A, Dahl IM, Gutteberg T, Skogen B (2004)
   Hepatitis B virus-infected peripheral blood progenitor cell harvests in liquid nitrogen freezer containing non-infectious products
   Transfusion, 44 (6), 942-3
   PubMed 15157265
5. Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E, Nordic Lymphoma Group study (2004)
   Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study
   Ann Hematol, 83 (7), 414-9
   PubMed 15085385
6. Jerkeman M, Leppä S, Kvaløy S, Holte H (2004)
   ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience
   Eur J Haematol, 73 (3), 179-82
   PubMed 15287915
7. Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E (2004)
   Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway
   Support Care Cancer, 12 (5), 312-8
   PubMed 14767750
8. Nermoen I, Foss A, Holte H, Mathisen Ø, Brekke IB, Line PD, Bergan A (2004)
   [Surgical treatment of hormone-producing adrenocortical carcinoma with liver metastases]
   Tidsskr Nor Laegeforen, 124 (23), 3061-3
   PubMed 15586188
9. Pettersen KI, Veenstra M, Guldvog B, Kolstad A (2004)
   The Patient Experiences Questionnaire: development, validity and reliability
   Int J Qual Health Care, 16 (6), 453-63
   PubMed 15557355
10. Risberg T, Bremnes Y, Kolstad A, Holte H, Wist E, Mella O, Klepp O (2004)
    [Should complementary therapies be offered in hospitals?]
    Tidsskr Nor Laegeforen, 124 (23), 3078-80
    PubMed 15586193
11. Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR (2004)
    Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway
    Eur J Cancer, 40 (4), 529-35
    PubMed 14962719
12. Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H (2004)
    Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
    Ann Oncol, 15 (7), 1072-8
    PubMed 15205201

Publications 2003

1. Andersen NS, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K, Langholm R, Ralfkiaer E, Akerman M, Eriksson M, Kuittinen O, Geisler CH, Nordic Lymphoma Group (2003)
   Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant
   Eur J Haematol, 71 (2), 73-80
   PubMed 12890145
2. Kvaløy S (2003)
   [Norwegian program for malignant lymphomas]
   Tidsskr Nor Laegeforen, 123 (7), 914
   PubMed 12737057
3. Linderoth J, Jerkeman M, Cavallin-Ståhl E, Kvaløy S, Torlakovic E, Nordic Lymphoma Group Study (2003)
   Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study
   Clin Cancer Res, 9 (2), 722-8
   PubMed 12576441
4. Osby E, Hagberg H, Kvaløy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Björkholm M, Nordic Lymphoma Group (2003)
   CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
   Blood, 101 (10), 3840-8
   PubMed 12531794
5. Risberg T, Kolstad A (2003)
   [Alternative medicine--attitudes and use among physicians, nurses and administrative staff employed in hospitals in northern Norway]
   Tidsskr Nor Laegeforen, 123 (5), 604-6
   PubMed 12683182
6. Risberg T, Kolstad A (2003)
   [Mental distress and use of alternative medicine among cancer patients]
   Tidsskr Nor Laegeforen, 123 (5), 607-9
   PubMed 12683183
7. Risberg T, Kolstad A, Wist EA, Holte H, Mella O, Klepp O (2003)
   [Should alternative therapists treat cancer--what is the opinion of oncology health personnel?]
   Tidsskr Nor Laegeforen, 123 (21), 3059-61
   PubMed 14618177
8. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM (2003)
   Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
   J Exp Med, 198 (6), 851-62
   PubMed 12975453
9. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (2003)
   The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
   Cancer Cell, 3 (2), 185-97
   PubMed 12620412
10. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, Doorduijn JK, Sydes MR, Kvalheim G (2003)
    High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial
    J Clin Oncol, 21 (21), 3918-27
    PubMed 14517188

Publications 2002

1. Abrahamsen AF, Andersen A, Nome O, Jacobsen AB, Holte H, Abrahamsen JF, Kvaloy S (2002)
   Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
   Ann. Oncol., 13 (11), 1786-1791
2. Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S (2002)
   Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
   Ann Oncol, 13 (11), 1786-91
   PubMed 12419752
3. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (2002)
   Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model
   Ann Oncol, 13 (7), 1099-107
   PubMed 12176790
4. Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002)
   [Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma]
   Tidsskr Nor Laegeforen, 122 (4), 364-9
   PubMed 11915663
5. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2002)
   The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
   N Engl J Med, 346 (25), 1937-47
   PubMed 12075054
6. Aamot H, Micci F, Holte H, Delabie J, Heim S (2002)
   M-FISH cytogenetic analysis of non-Hodgkin lymphomas with t(14;18)(q32;q21) and add(1)(p36) as a secondary abnormality shows that the extra material often comes from chromosome arm 17q
   Leuk Lymphoma, 43 (5), 1051-6
   PubMed 12148885

Publications 2001

1. Aurlien E, Holte H, Kvaloy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
   Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
   Eur. J. Haematol., 66 Suppl 64, 14-20
2. Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
   Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
   Eur J Haematol Suppl, 64, 14-20
   PubMed 11486395
3. Blystad AK, Enblad G, Kvaløy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001)
   High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
   Bone Marrow Transplant, 27 (7), 711-6
   PubMed 11360110
4. Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G (2001)
   High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells
   Bone Marrow Transplant, 28 (9), 849-57
   PubMed 11781645
5. Blystad AK, Torlakovic E, Holte H, Kvaløy S, Lenschow E, Kvalheim G (2001)
   CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD
   Cytotherapy, 3 (4), 295-305
   PubMed 12171718
6. Hall KS, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer HH, Andersen A, Skovlund E, Bergh J, Hall C (2001)
   Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients
   Breast Cancer Res Treat, 67 (3), 235-44
   PubMed 11561769
7. Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, Cavallin-Stahl E (2001)
   Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial
   Med Oncol, 18 (1), 85-94
   PubMed 11778974
8. Nordøy T, Husebekk A, Aaberge IS, Jenum PA, Samdal HH, Flugsrud LB, Kristoffersen AC, Holte H, Kvaløy S, Kolstad A (2001)
   Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines
   Bone Marrow Transplant, 28 (7), 681-7
   PubMed 11704791
9. Stokke T, DeAngelis P, Smedshammer L, Galteland E, Steen HB, Smeland EB, Delabie J, Holte H (2001)
   Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma
   Br J Cancer, 85 (12), 1900-13
   PubMed 11747333
10. Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH (2001)
    High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group
    J Clin Oncol, 19 (11), 2927-36
    PubMed 11387366
11. Tanum G, Olsen DR, Grøttum K, Mjåland S, Kvaløy S, Jetne V, Kvinnsland S (2001)
    [The radiotherapy satellite in Kristiansand--a model for Norwegian regional hospitals?]
    Tidsskr Nor Laegeforen, 121 (18), 2179-82
    PubMed 11571996

Publications 2000

1. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000)
   Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
   Lancet, 356 (9239), 1384-91
   PubMed 11052580
2. Hollender A, Kvaloy S, Lote K, Nome O, Holte H (2000)
   Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis
   Eur J Cancer, 36 (14), 1762-8
   PubMed 10974623
3. Knobel H, Loge JH, Nordøy T, Kolstad AL, Espevik T, Kvaløy S, Kaasa S (2000)
   High level of fatigue in lymphoma patients treated with high dose therapy
   J Pain Symptom Manage, 19 (6), 446-56
   PubMed 10908825
4. Lote K, Holte H, Kvaloy S (2000)
   Testicular lymphoma is associated with a high risk of extranodal recurrence
   Cancer, 89 (3), 713-4
   PubMed 10931479
5. Lote K, Holte H, Nome O, Langholm R, Kvaløy S (2000)
   Stage I high-grade non-Hodgkin's lymphoma
   Acta Oncol, 39 (7), 865-72
   PubMed 11145446
6. Schouten HC, Kvaloy S, Sydes M, Qian W, Fayers PM (2000)
   The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)
   Ann Oncol, 11 Suppl 1, 91-4
   PubMed 10707787
7. Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, Børresen-Dale AL, DeAngelis P, Steen HB (2000)
   Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma
   Int J Cancer, 89 (4), 313-24
   PubMed 10956404

Publications 1999

1. Abrahamsen AF, Loge JH, Hannisdal E, Nome O, Lund MB, Holte H, Kvaløy S (1999)
   Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease
   Acta Oncol, 38 (4), 511-5
   PubMed 10418720
2. Andersen A, Holte H, Slørdal L (1999)
   Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients
   Cancer Chemother Pharmacol, 44 (5), 422-6
   PubMed 10501917
3. Blystad A, Kvalheim G, Torlakovic E, Holte H, Jacobsen E, Beiske K, Vâlerhaugen H, Lenschow E, Kvaloy S (1999)
   High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma
   Bone Marrow Transplant, 24 (8), 865-72
   PubMed 10516698
4. Galteland E, Holte H, Stokke T (1999)
   c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization
   Cytometry, 38 (2), 53-60
   PubMed 10323217
5. Hjermstad M, Holte H, Evensen S, Fayers P, Kaasa S (1999)
   Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?
   Bone Marrow Transplant, 24 (8), 911-8
   PubMed 10516705
6. Holte H, Suo Z, Smeland EB, Kvaløy S, Langholm R, Stokke T (1999)
   Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
   Acta Oncol, 38 (4), 495-503
   PubMed 10418718
7. Jerkeman M, Anderson H, Cavallin-Ståhl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaløy S, Sundström C, Akerman M (1999)
   CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial
   Ann Oncol, 10 (9), 1079-86
   PubMed 10572606
8. Lindman H, Wiklund T, Holte H, Ljungman P, Blomqvist C, Kvalheim G, Bengtsson M, Höglund M, Wilking N, Bergh J (1999)
   FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group
   Acta Oncol, 38 (2), 239-45
   PubMed 10227447
9. Nordøy T, Kolstad A, Endresen P, Holte H, Kvaløy S, Kvalheim G, Husebekk A (1999)
   Persistent changes in the immune system 4-10 years after ABMT
   Bone Marrow Transplant, 24 (8), 873-8
   PubMed 10516699

Publications 1998

1. Abrahamsen AF, Loge JH, Hannisdal E, Holte H, Kvaløy S (1998)
   Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution
   Eur J Cancer, 34 (12), 1865-70
   PubMed 10023307
2. Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G (1998)
   Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
   Bone Marrow Transplant, 21 (9), 873-8
   PubMed 9613778
3. Galteland E, Sivertsen EA, Lote K, Holte H, Kvaløy S (1998)
   [Primary non-Hodgkin's lymphoma of the brain]
   Tidsskr Nor Laegeforen, 118 (29), 4524-6
   PubMed 9889638
4. Ose T, Blaker B, Kvaløy S, Kolset T, Fluge G (1998)
   [The importance of nutrition for cancer patients]
   Tidsskr Nor Laegeforen, 118 (22), 3466-70
   PubMed 9800498
5. Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O, Steen HB (1998)
   Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas
   Br J Cancer, 77 (11), 1832-8
   PubMed 9667654
6. Stokke T, Smeland EB, Kvaløy S, Holte H (1998)
   Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas
   Br J Cancer, 77 (11), 1839-41
   PubMed 9667655

Publications 1997

1. Abrahamsen AF, Egeland T, Hansen S, Langholm R, Holte H, Kvaloy S (1997)
   Hodgkin's disease in a national and hospital population: Trends over 20 years
   Eur. J. Cancer, 33 (14), 2380-2383
2. Abrahamsen AF, Hoiby EA, Hannisdal E, Jorgensen OG, Holte H, Hasseltvedt V, Host H (1997)
   Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: A follow-up study 1994
   Eur. J. Haematol., 58 (2), 73-77
3. Foss Abrahamsen A, Egeland T, Hansen S, Langholm R, Holte H, Kvaløy S (1997)
   Hodgkin's disease in a national and hospital population: trends over 20 years
   Eur J Cancer, 33 (14), 2380-3
   PubMed 9616285
4. Foss Abrahamsen A, Høiby EA, Hannisdal E, Jørgensen OG, Holte H, Hasseltvedt V, Høst H (1997)
   Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994
   Eur J Haematol, 58 (2), 73-7
   PubMed 9111586
5. Gundersen S, Kvaløy S, Hannisdal E (1997)
   [Check up of breast cancer stages 1 and 2]
   Tidsskr Nor Laegeforen, 117 (8), 1079-81
   PubMed 9148472
6. Lien HH, Blomlie V, Blystad AK, Holte H, Langholm R, Kvaløy S (1997)
   Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement
   Acta Radiol, 38 (5), 896-902
   PubMed 9332252
7. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE (1997)
   A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
   Br J Haematol, 98 (3), 711-8
   PubMed 9332329

Publications 1996

1. Abrahamsen AF, Hannisdal E, Nome O, Elgio RF, Holte H, Hager B, Langholm R, Kvaløy S (1996)
   Prognostic variables and results of salvage treatment in Hodgkin's disease
   Acta Oncol, 35 Suppl 8, 67-72
   PubMed 9073050
2. Abrahamsen AF, Hannisdal E, Nome O, Holte H, Hager B, Langholm R, Kvaløy S (1996)
   Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution
   Ann Oncol, 7 (2), 145-50
   PubMed 8777170
3. Holte H, Kvaløy SO, Engan T, Evensen SA, Mella O, Tangen JM, Wesenberg F, Wist EA (1996)
   [High dose therapy with autologous stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services]
   Tidsskr Nor Laegeforen, 116 (21), 2577-81
   PubMed 8928130
4. Holte H, Mella O, Wist E, Telhaug R, Hannisdal E, Abrahamsen AF (1996)
   ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease
   Acta Oncol, 35 Suppl 8, 73-80
   PubMed 9073051
5. Kolstad A, Holte H, Kvaløy S, Jakobsen E, Erikstein B, Aurlien E, Kvalheim G, Bøhler PJ, Langholm R (1996)
   [High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]
   Tidsskr Nor Laegeforen, 116 (21), 2547-51
   PubMed 8928122
6. Kvalheim G, Holte H, Jakobsen E, Kvaloy S (1996)
   Immunomagnetic purging of lymphoma cells from autografts
   J Hematother, 5 (5), 561-2
   PubMed 8938530
7. Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB (1996)
   [High-dose therapy of cancer with CD34 positive cells as stem cell support]
   Tidsskr Nor Laegeforen, 116 (21), 2542-6
   PubMed 8928121
8. Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O (1996)
   Purging of tumor cells from leukapheresis products: experimental and clinical aspects
   J Hematother, 5 (4), 427-36
   PubMed 8877718
9. Lien HH, Holte H (1996)
   Fat replacement of Hodgkin disease of bone marrow after chemotherapy: report of three cases
   Skeletal Radiol, 25 (7), 671-4
   PubMed 8915054
10. Sletnes KE, Holte H, Halvorsen S, Jakobsen E, Wisløff F, Kvaløy S (1996)
    Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma
    Bone Marrow Transplant, 17 (4), 577-81
    PubMed 8722358
11. Waage A, Dahl IM, Evensen SA, Holte H, Lamvik J, Sletnes K, Wisløff F (1996)
    [Treatment with growth factors and cytokines in hematologic diseases]
    Tidsskr Nor Laegeforen, 116 (12), 1465-9
    PubMed 8650635

Publications 1995

1. Kvaløy S (1995)
   [Quality assurance in health care--a paper tiger?]
   Tidsskr Nor Laegeforen, 115 (26), 3235-6
   PubMed 7482449
2. AAS M, LIEN HH, NOME O, WINDEREN M, HAGER B, KVALOY S, ABRAHAMSEN AF (1995)
   GA-67 SCINTIGRAPHY, MRI AND CT IN THE FOLLOW-UP OF MALIGNANT LYMPHOMA PATIENTS WITH RESIDUAL MEDIASTINAL MASS
   ADV PHAR SC, 51-56

Publications 1994

1. Abrahamsen AF, Lien HH, Aas M, Winderen M, Hager B, Kvaløy S, Elgjo RF, Nome O (1994)
   Magnetic resonance imaging and 67gallium scan in mediastinal malignant lymphoma: a prospective pilot study
   Ann Oncol, 5 (5), 433-6
   PubMed 8075050
2. Kavløy S, Holte H, Kvalheim G (1994)
   [High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]
   Tidsskr Nor Laegeforen, 114 (19), 2240-1
   PubMed 7992286
3. Kvalheim G, Jakobsen E, Holte H, Beiske K, Langholm R, Høiby A, Wang MY, Funderund S, Fodstad O, Smeland E (1994)
   Autologous bone marrow transplantation of non-Hodgkin's lymphoma patients with marrow purged using immunomagnetic beads
   Prog Clin Biol Res, 389, 133-8
   PubMed 7700895

Publications 1993

1. ABRAHAMSEN JF, ANDERSEN A, HANNISDAL E, NOME O, ABRAHAMSEN AF, KVALOY S, HOST H (1993)
   2ND MALIGNANCIES AFTER TREATMENT OF HODGKINS-DISEASE - THE INFLUENCE OF TREATMENT, FOLLOW-UP TIME, AND AGE
   J. Clin. Oncol., 11 (2), 255-261
2. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaløy S, Høst H (1993)
   Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age
   J Clin Oncol, 11 (2), 255-61
   PubMed 8426202
3. Erikstein BK, Holte H, Kvaløy S, Andersson KB, Steen HB, Hannisdal E, Smeland EB (1993)
   Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas
   Br J Haematol, 83 (3), 392-8
   PubMed 8097923
4. Hannisdal E, Gundersen S, Kvaløy S, Lindegaard MW, Aas M, Finnanger AM, Jørgensen OG, Theodorsen L, Høst H (1993)
   Follow-up of breast cancer patients stage I-II: a baseline strategy
   Eur J Cancer, 29A (7), 992-7
   PubMed 8098950
5. Slørdahl SH, Smeland EB, Holte H, Grønn M, Lie SO, Seip M (1993)
   Leukemic blasts with markers of four cell lineages in Down's syndrome ("megakaryoblastic leukemia")
   Med Pediatr Oncol, 21 (4), 254-8
   PubMed 8469219

Publications 1992

1. Abrahamsen AF, Jakobsen E, Langholm R, Abrahamsen JF, Kvaløy S, Nome O (1992)
   Bone marrow examination in Hodgkin's disease
   Acta Oncol, 31 (1), 41-2
   PubMed 1586503
2. Stokke T, Holte H, Smeland EB, Lie SO, Steen HB (1992)
   Differential chromatin structure-dependent binding of 7-aminoactinomycin D in normal and malignant bone marrow hematopoietic cells
   Cancer Res, 52 (18), 5007-12
   PubMed 1516056
3. Wang MY, Kvalheim G, Kvaløy S, Beiske K, Jakobsen E, Wijdenes J, Pihl A, Fodstad O (1992)
   An effective immunomagnetic method for bone marrow purging in T cell malignancies
   Bone Marrow Transplant, 9 (5), 319-23
   PubMed 1617315

Publications 1991

1. Alfsen GC, Beiske K, Holte H, Hovig E, Deggerdal A, Sandlie I, Widing E, Slørdahl S, Klepper LK, Sizoo W (1991)
   T-cell receptor tau delta +/CD3+4-8-T- cell acute lymphoblastic leukemias: a distinct subgroup of leukemias in children. A report of five cases
   Blood, 77 (9), 2023-30
   PubMed 1826854
2. Holte H (1991)
   [Resistance to chemotherapeutic agents in the treatment of cancer. Emphasizing the multiresistant phenotype]
   Tidsskr Nor Laegeforen, 111 (19), 2423-7
   PubMed 1926080
3. Lømo J, Smeland EB, Stokke T, Holte H, Funderud S, Blomhoff HK (1991)
   Differential effects of interferon-gamma and low molecular weight BCGF on growth of human B lymphocytes; interferon-gamma prolongs the increased c-MYC mRNA levels after activation
   Scand J Immunol, 33 (4), 365-73
   PubMed 1902001
4. Nome O, Kvaløy S, Abrahamsen AF, Giercksky KE, Langholm R (1991)
   [Non-Hodgkin's lymphoma in the gastrointestinal tract]
   Tidsskr Nor Laegeforen, 111 (1), 59-60
   PubMed 2000590
5. Stokke T, Erikstein B, Holte H, Funderud S, Steen HB (1991)
   Cell cycle-specific expression and nuclear binding of DNA polymerase alpha
   Mol Cell Biol, 11 (6), 3384-9
   PubMed 2038340
6. Stokke T, Holte H, Erikstein B, Davies CL, Funderud S, Steen HB (1991)
   Simultaneous assessment of chromatin structure, DNA content, and antigen expression by dual wavelength excitation flow cytometry
   Cytometry, 12 (2), 172-8
   PubMed 1710961
7. Wibe E, Kvaløy S, Nome O, Abrahamsen AF, Bjørgo S (1991)
   [Tumor lysis syndrome. A life-threatening complication during cytostatic treatment of chemosensitive types of cancer]
   Tidsskr Nor Laegeforen, 111 (19), 2435-7
   PubMed 1926084

Publications 1990

1. Abrahamsen AF, Borge L, Holte H (1990)
   Infection after splenectomy for Hodgkin's disease
   Acta Oncol, 29 (2), 167-70
   PubMed 2334569
2. BRINCH L, HANNISDAL E, ABRAHAMSEN AF, KVALOY S, LANGHOLM R (1990)
   EXTRAMEDULLARY PLASMACYTOMAS AND SOLITARY PLASMA-CELL TUMORS OF BONE
   Eur. J. Haematol., 44 (2), 131-134
3. Brinch L, Hannisdal E, Abrahamsen AF, Kvaløy S, Langholm R (1990)
   [Diagnosis and treatment of solitary plasmacytoma]
   Tidsskr Nor Laegeforen, 110 (12), 1515-6
   PubMed 2339400
4. Brinch L, Hannisdal E, Abrahamsen AF, Kvaløy S, Langholm R (1990)
   Extramedullary plasmacytomas and solitary plasma cell tumours of bone
   Eur J Haematol, 44 (2), 132-5
   PubMed 2318296
5. Funderud S, Erikstein B, Asheim HC, Nustad K, Stokke T, Blomhoff HK, Holte H, Smeland EB (1990)
   Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation
   Eur J Immunol, 20 (1), 201-6
   PubMed 1689662
6. Kaasa S, Kvaløy S, Dicato MA, Ries F, Huys JV, Royer E, Carruthers L (1990)
   A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group
   Eur J Cancer, 26 (3), 311-4
   PubMed 2141487
7. Smeland EB, Holte H, Kiil Blomhoff H, Asheim HC, Stokke T, Torjesen P, Funderud S (1990)
   Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45)
   Scand J Immunol, 31 (5), 583-91
   PubMed 1693226
8. Stokke T, Holte H, Davies CD, Steen HB, Lie SO (1990)
   Quenching of Hoechst 33258 fluorescence in erythroid precursors
   Cytometry, 11 (6), 686-90
   PubMed 1696537

Publications 1989

1. Gravdahl HK, Beiske K, Langholm R, Kvaløy S, Marton PF (1989)
   [Giant cell anaplastic anemia]
   Tidsskr Nor Laegeforen, 109 (23), 2289-94
   PubMed 2772896
2. Holte H, Blomhoff HK, Beiske K, Funderud S, Torjesen P, Gaudernack G, Stokke T, Smeland EB (1989)
   Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens
   Eur J Immunol, 19 (7), 1221-5
   PubMed 2547623
3. Holte H, de Lange Davies C, Beiske K, Stokke T, Marton PF, Smeland EB, Høie J, Kvaløy S (1989)
   Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma
   Int J Cancer, 44 (6), 975-80
   PubMed 2606582
4. Holte H, Stokke T, Smeland E, Watt R, Blomhoff HK, Kaalhus O, Ohlsson R (1989)
   Levels of myc protein, as analyzed by flow cytometry, correlate with cell growth potential in malignant B-cell lymphomas
   Int J Cancer, 43 (1), 164-70
   PubMed 2642893

Publications 1988

1. Beiske K, Clark EA, Holte H, Ledbetter JA, Smeland EB, Godal T (1988)
   Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets
   Int J Cancer, 42 (4), 521-8
   PubMed 2459071
2. Holte H, Torjesen P, Blomhoff HK, Ruud E, Funderud S, Smeland EB (1988)
   Cyclic AMP has the ability to influence multiple events during B cell stimulation
   Eur J Immunol, 18 (9), 1359-66
   PubMed 2458941
3. Kvalheim G, Funderud S, Kvaløy S, Gaudernack G, Beiske K, Jakobsen E, Jacobsen AB, Pihl A, Fodstad O (1988)
   Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation
   J Natl Cancer Inst, 80 (16), 1322-5
   PubMed 3050139
4. Stokke T, Holte H, Steen HB (1988)
   In vitro and in vivo activation of B-lymphocytes: a flow cytometric study of chromatin structure employing 7-aminoactinomycin D
   Cancer Res, 48 (23), 6708-14
   PubMed 3263191

Publications 1987

1. Holte H, Davies CD, Kvaløy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T (1987)
   The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas
   Int J Cancer, 39 (5), 590-4
   PubMed 3106247
2. Holte H, Saeter G, Dahl IM, Abrahamsen AF (1987)
   Progressive loss of vision in patients with high-grade non-Hodgkin's lymphoma
   Cancer, 60 (10), 2521-3
   PubMed 3664433
3. Lømo J, Holte H, de Lange Davies C, Ruud E, Laukas M, Smeland EB, Godal T, Blomhoff HK (1987)
   Downregulation of c-myc RNA is not a prerequisite for reduced cell proliferation, but is associated with G1 arrest in B-lymphoid cell lines
   Exp Cell Res, 172 (1), 84-91
   PubMed 3115797
4. Smeland EB, Beiske K, Ohlsson R, Holte H, Ruud E, Blomhoff HK, Jefferis R, Godal T (1987)
   Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells
   J Immunol, 138 (10), 3179-84
   PubMed 3553323
5. Smeland EB, Blomhoff HK, Holte H, Ruud E, Beiske K, Funderud S, Godal T, Ohlsson R (1987)
   Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes
   Exp Cell Res, 171 (1), 213-22
   PubMed 2442015

Publications 1986

1. Gundersen S, Kvinnsland S, Klepp O, Kvaløy S, Lund E, Høst H (1986)
   Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial
   Eur J Cancer Clin Oncol, 22 (12), 1431-4
   PubMed 3595668
2. Schjølseth SA, Bøhler PJ, Marton P, Holte H (1986)
   [Lymphomatoid granulomatosis]
   Tidsskr Nor Laegeforen, 106 (25), 2056-7, 2082
   PubMed 3775730

Publications 1985

1. KVALOY S, MARTON PF, KAALHUS O, HOIE J, FOSSABRAHAMSEN A, GODAL T (1985)
   THYMIDINE-H-3 UPTAKE IN B-CELL LYMPHOMAS - RELATIONSHIP TO TREATMENT RESPONSE AND SURVIVAL
   SCAND J HAEMATOL, 34 (5), 429-435
2. Kvaløy S, Langholm R, Kaalhus O, Marton PF, Høst H, Godal T (1985)
   Immunologic subsets in B cell lymphomas defined by surface immunoglobulin isotype and complement receptor--their relationship to survival
   Scand J Haematol, 35 (2), 137-44
   PubMed 3876595
3. Kvaløy S, Marton PF, Kaalhus O, Høie J, Foss-Abrahamsen A, Godal T (1985)
   3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival
   Scand J Haematol, 34 (5), 429-35
   PubMed 3925545
4. Melsom H, Kvaløy S, Beiske K, Funderud S, Marton PF, Godal T, Lie SO (1985)
   [Monoclonal antibodies. A new tool in the diagnosis of leukemia and lymphoma]
   Tidsskr Nor Laegeforen, 105 (22), 1379-82
   PubMed 4049331

Publications 1984

1. Kvaløy S, Langholm R, Kaalhus O, Michaelsen T, Funderud S, Foss Abrahamsen A, Godal T (1984)
   Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas
   Int J Cancer, 33 (2), 173-7
   PubMed 6319299
2. Onsrud M, Kvaløy S (1984)
   Influence of progestogen therapy on T lymphocyte subsets
   Acta Pathol Microbiol Immunol Scand C, 92 (1), 89-91
   PubMed 6608858
3. Stensvold K, Brandtzaeg P, Kvaløy S, Seip M, Lie SO (1984)
   Immunoblastic lymphadenopathy with early onset in two boys: immunohistochemical study and indication of decreased proportion of circulating T-helper cells
   Br J Haematol, 56 (3), 417-30
   PubMed 6230099

Publications 1983

1. Gundersen S, Kvaløy S, Fosså SD, Høst H (1983)
   [Ovarian irridation and prednisone versus tamoxifen (Nolvadex) in advanced breast cancer]
   Tidsskr Nor Laegeforen, 103 (27), 1873-5
   PubMed 6359581
2. KVALOY S, ABRAHAMSEN AF, LANDAAS TO, LANGHOLM R, MARTON PF (1983)
   SOLITARY PLASMACYTOMAS OF BONE
   SCAND J HAEMATOL, 30 Suppl 39, 23-29
3. KVALOY S, LINDMO T, DAVIES C, WISLOFF F, GODAL T (1983)
   SEZARY CELLS WITH AN UNUSUAL PHENOTYPE, THEIR MODULATION WITH 12-O-TETRADECANOYL PHORBOL-13-ACETATE (TPA) INVITRO, AND THEIR RELATIONSHIP TO T-CELL DEVELOPMENT
   J. Clin. Immunol., 3 (3), 212-221
4. Kvaløy S, Lindmo T, Davies C, Wisløff F, Godal T (1983)
   Sézary cells with an unusual phenotype, their modulation with 12-O-tetradecanoyl phorbol-13-acetate (TPA) in vitro, and their relationship to T-cell development
   J Clin Immunol, 3 (3), 212-21
   PubMed 6604064

Publications 1982

1. Kvaløy S, Marton PF, Høst H, Solheim BG, Godal T (1982)
   Distribution of T-cell subsets identified by monoclonal antibodies in cell suspensions from lymph node biopsies of human B-cell lymphomas
   Scand J Haematol, 28 (4), 293-305
   PubMed 6981200
2. Wells A, Godal T, Kvaløy S, Steen HB, Klein G (1982)
   Quantitative comparison of Epstein-Barr virus receptor expression on sIgM and sIgG cell lines and B-cell lymphoma biopsies
   Differentiation, 22 (2), 113-9
   PubMed 6290303

Publications 1981

1. Kvaløy S, Godal T, Marton PF, Steen H, Brenhovd IO, Abrahamsen AF (1981)
   Spontaneous (H)-thymidine uptake in histological subgroups of human B-cell lymphomas
   Scand J Haematol, 26 (3), 221-34
   PubMed 7015478
2. Landaas TO, Godal T, Marton PF, Kvaløy S, Langholm R, Lindmo T, Jørgensen OG, Høst H (1981)
   Cell-associated immunoglobulin in human non-Hodgkin lymphomas. A comparative study of surface immunoglobulin on cells in suspension and cytoplasmic immunoglobulin by immunohistochemistry
   Acta Pathol Microbiol Scand A, 89 (2), 91-101
   PubMed 7023187

Publications 1980

1. Godal T, Kvaløy S, Heier HE (1980)
   [Antibody synthesis biology. A theme with variations--from amino acid sequence and regulatory cell circuits to malignant lymphomas]
   Tidsskr Nor Laegeforen, 100 (19-21), 1214-8
   PubMed 6968461
2. KVALOY S (1980)
   MAN, NATURE AND MECHANISTIC SYSTEMS - AN EXERCISE IN ECOPHILOSOPHY
   ALTERNATIVE FUTURES, 3 (3), 32-46

Publications 1979

1. KVALOY S (1979)
   MAN, NATURE, AND MECHANISTIC SYSTEMS - EXERCISE IN ECO-PHILOSOPHY
   North Am. Rev., 264 (3), 35-37
2. Sanner T, Brennhovd I, Christensen I, Jørgensen O, Kvaløy S (1979)
   Cellular antitumor immune response in women with risk factors for breast cancer
   Cancer Res, 39 (2 Pt 2), 654-7
   PubMed 761231

Publications 1978

1. Klepp O, Kvaløy S (1978)
   [Tissue necrosis caused by careless injection of cytostatic agents]
   Tidsskr Nor Laegeforen, 98 (27), 1330-1
   PubMed 694872